The CDC page outlines the importance of medication-assisted treatment (MAT) for opioid use disorder (OUD) during pregnancy, emphasizing methadone and buprenorphine as effective options to improve maternal and neonatal outcomes. It also highlights the need for comprehensive care, including mental health support, to reduce relapse risks and manage withdrawal symptoms in newborns.
This guide reviews ways that telehealth modalities can be used to provide treatment for serious mental illness and substance use disorders among adults, distills the research into recommendations for practice, and provides examples of how these recommendations can be implemented.
Learning Objectives:
By the end of this training people will know:
The history of overdose prevention and opioid antagonist distribution for community members, including available formulations of antagonists
State of the research on opioid antagonist distribution, utilization, and outcome in the community
Evidence-based practices for overdose response and opioid antagonist administration
This SAMHSA manual offers best practices to states, tribes, and local communities on collaborative treatment approaches for pregnant women living with opioid use disorders, and the risks and benefits associated with medication-assisted treatment.
This Clinical Guide provides comprehensive, national guidance for optimal management of pregnant and parenting women with opioid use disorder and their infants. The Clinical Guide helps healthcare professionals and patients determine the most clinically appropriate action for a particular situation and informs individualized treatment decisions.
This website is a database of behavioral health providers in Nevada specializing in substance use disorder and co-occurring mental health disorder treatment services. All agencies listed are Certified by the Division, SAPTA (Substance Abuse Prevention and Treatment Agency).